Földes Iván, Dávid Károly, Horváth Gábor, Osztrogonácz Henrik, Jankovics Katalin, Tolvaj Gyula
BM Központi Kórház és Intézményei, Izotóp Osztály, Budapest.
Orv Hetil. 2004 Jun 6;145(23):1211-6.
Many studies have explored that thyroid dysfunctions can be induced by cytokine therapy. Most observations were collected in connection with the treatment of viral hepatitis with interferon-alpha.
Frequency and types of thyroid dysfunction developed during and after recombinant interferon-alpha treatment were studied in 138 patients with viral hepatitis C or B. Therapy lasted 12 months or more, subjects having thyroid dysfunction at the start of therapy were excluded from the study. Thyroid parameters (TSH, FT4, FT3 and anti-TPO) were controlled every third month. In patients in whom thyroid dysfunction occurred the measurements were repeated monthly and other tests were also performed (anti-Tg, IL-6, TSH receptor antibody, thyroid scan and 99mTc-pertechnetate uptake).
Thyroid function disturbances were found in 30 (21.7%) patients, 12 of them (8.7%) showed persistent hypothyroidism. Hyperthyroidism was transitory in all cases. The clinical course of thyroid dysfunction might be monophasic (hyper- or hypothyroidism), biphasic (hyperthyroidism followed by hypofunction) or triphasic. Immune and non-immune forms can be clearly distinguished.
Every fifth patient with chronic hepatitis showed thyroid dysfunction during interferon-alpha therapy, it is necessary therefore to control the hormonal status and the thyroid antibody titer. Treated patients have to be informed in advance that as a "side effect" persistent hypothyroidism may develop.
许多研究已探讨细胞因子疗法可诱发甲状腺功能障碍。大多数观察结果是在使用α干扰素治疗病毒性肝炎的过程中收集的。
对138例丙型或乙型病毒性肝炎患者在重组α干扰素治疗期间及之后出现的甲状腺功能障碍的频率和类型进行了研究。治疗持续12个月或更长时间,治疗开始时患有甲状腺功能障碍的受试者被排除在研究之外。每三个月检测一次甲状腺参数(促甲状腺激素、游离甲状腺素、游离三碘甲状腺原氨酸和抗甲状腺过氧化物酶)。对于出现甲状腺功能障碍的患者,每月重复测量并进行其他检查(抗甲状腺球蛋白、白细胞介素-6、促甲状腺激素受体抗体、甲状腺扫描和99m锝高锝酸盐摄取)。
30例(21.7%)患者出现甲状腺功能紊乱,其中12例(8.7%)表现为持续性甲状腺功能减退。所有病例中的甲状腺功能亢进均为暂时性。甲状腺功能障碍的临床病程可能为单相(甲状腺功能亢进或减退)、双相(甲状腺功能亢进后功能减退)或三相。免疫性和非免疫性形式可明确区分。
每五分之一的慢性肝炎患者在α干扰素治疗期间出现甲状腺功能障碍,因此有必要监测激素状态和甲状腺抗体滴度。必须提前告知接受治疗的患者,可能会出现持续性甲状腺功能减退这一“副作用”。